Saint Luke's Mid America Heart Institute and the University of Missouri-Kansas City, Department of Biomedical and Health Informatics, Kansas City, Missouri.
Saint Luke's Mid America Heart Institute and the University of Missouri-Kansas City, Department of Biomedical and Health Informatics, Kansas City, Missouri.
J Am Coll Cardiol. 2020 Nov 17;76(20):2379-2390. doi: 10.1016/j.jacc.2020.09.542.
To improve the patient-centeredness of care, patient-reported outcomes have been increasingly used to quantify patients' symptoms, function, and quality of life. In heart failure, the Kansas City Cardiomyopathy Questionnaire (KCCQ) has been qualified by the U.S. Food and Drug Administration as a Clinical Outcome Assessment and recommended as a performance measure for quantifying the quality of care. By systematically asking the same questions reproducibly over time, the KCCQ can validly and sensitively capture the impact of heart failure on patients' lives and is strongly associated with clinical events over time. This review describes how to interpret the KCCQ, how it should be analyzed in clinical trials to maximize the interpretability of results, and how it can be used in clinical practice and population health. By providing a deeper understanding of the KCCQ, it is hoped that its use can further improve the patient-centeredness of heart failure care.
为了提高医疗的以患者为中心程度，患者报告的结果已被越来越多地用于量化患者的症状、功能和生活质量。在心力衰竭中，堪萨斯城心肌病问卷 (KCCQ) 已被美国食品和药物管理局 (FDA) 定性为临床结局评估，并被推荐作为量化护理质量的绩效指标。通过随着时间的推移系统地重复询问相同的问题，KCCQ 可以有效地、敏感地捕捉心力衰竭对患者生活的影响，并且与随着时间推移的临床事件密切相关。这篇综述描述了如何解释 KCCQ，如何在临床试验中分析它以最大限度地提高结果的可解释性，以及如何在临床实践和人群健康中使用它。通过更深入地了解 KCCQ，希望它的使用可以进一步提高心力衰竭护理的以患者为中心程度。
